Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445428 | 0.98 | TSHR (0.36) | TDP1TSHRATMHRH3 | |
| SCHEMBL6443996 | 0.98 | TSHR (0.36) | TDP1TSHRATMHRH3 | |
| Hydrochloric Acid SCHEMBL8482930 | 0.95 | TSHR (0.35) | TDP1TSHRATMHRH3 | |
| SCHEMBL11501574 | 0.84 | LMNA (0.36) | TDP1TSHRATMHRH3CARM1 | |
| SCHEMBL11483109 | 0.79 | SMN1; SMN2 (0.37) | TSHRHRH3LMNA | |
| SCHEMBL12717852 | 0.77 | LMNA (0.38) | TDP1TSHRATMHRH3CARM1 | |
| SCHEMBL3272365 | 0.75 | ATM (0.34) | TDP1TSHRATMCARM1PRMT6 | |
| SCHEMBL2783147 | 0.75 | CYP2D6 (0.43) | TDP1TSHRATMCARM1PRMT6 | |
| SCHEMBL12718302 | 0.75 | ALDH1A1 (0.37) | TSHRHRH3LMNA | |
| SCHEMBL7050630 | 0.75 | LMNA (0.36) | TDP1TSHRATMCARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
| EP-2294065-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | Vernalis (R&D) Ltd. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
| US-6858679-B2 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030153693-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | QUIRK RODERIC PAUL (US) | 2003-08-14 | — | — | US | disclosed |
| US-6605564-B1 | Anionic polymerization initiators and salt additives selected from sodium chloride, sodium iodide, potassium chloride, potassium t-butoxide, for increasing the efficiency of reactions between living polymer anions and electrophiles | FMC CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-6545103-B2 | Living polymers | FMC CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020010082-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | TDP1 377/4885TSHR 1206/4885ATM 112/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | TDP1 609/4885TSHR 2045/4885ATM 218/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | TDP1 377/4885TSHR 1206/4885ATM 112/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | TDP1 609/4885TSHR 2045/4885ATM 218/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | TDP1 609/4885TSHR 2045/4885ATM 218/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | TDP1 918/4885TSHR 1422/4885ATM 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.